This has to be a joke, but it's on the clinicaltrials.gov website. It's also on the R&D Pipleine for approvals on the Takeda website. Do they really think bringing Rozerem back to treat bipolar disorders is a good idea?
http://clinicaltrials.gov/show/NCT01677182
Rozerem does about 60M a year.
I can guarantee that Rozerem does nowhere near $60M a year, maybe 3-4yrs ago, not now, $30M a year if you are lucky.
The bi-polar indication is Sr. Mgmt grasping at straws hoping to save the train wreck that is Takeda with another blockbuster, it just won't happen until wholesale changes are made at the top.
Someone needs to tell these TAPpers running the show, Rozerem is no Prevacid. You can't turn everything into a TAB or a PAC and be successful at it. Prevacid was a one hit wonder for these guys.
Decisions like developing Rozerem for BP are made way above Doug Cole's pay grade. He has little say in what is developed by R&D.
Study was terminated. Maybe there's more than, just getting a good nights sleep, to treating bi polar disorder. Rozerem will be generic in a few years, we are not selling it people.This has to be a joke, but it's on the clinicaltrials.gov website. It's also on the R&D Pipleine for approvals on the Takeda website. Do they really think bringing Rozerem back to treat bipolar disorders is a good idea?
http://clinicaltrials.gov/show/NCT01677182
Someone needs to tell these TAPpers running the show, Rozerem is no Prevacid. You can't turn everything into a TAB or a PAC and be successful at it. Prevacid was a one hit wonder for these guys.
Thanks tough guy
Please. You are a clown. Use your real name when you talk smack about legacy Takeda reps. There is no difference between the two.
"Use your real name," said anonymous
